

CURRICULUM VITAE

I. PERSONAL DATA

Name: Ercem S. Atillasoy, MD, FAAD

II. EDUCATION AND TRAINING

<u>School</u>	<u>Date</u>	<u>Major/Minor Courses</u>	<u>Degree</u>
Hunter College High School NYC, NY	1982		HS Diploma
City University of New York Brooklyn, NY (Honors, BA-MD program)	1986	English	B.A., Honors
Yale Medical School Yale University New Haven, CT	1991		M.D.
Yale- New Haven Hospital Dept of Internal Medicine Yale Medical School New Haven, CT	1992	Medical Internship	Completion
University of Pennsylvania Department of Dermatology Philadelphia, PA	1995	Dermatology Residency	Completion
Wharton School University of Pennsylvania Philadelphia, PA	2004	Executive Education	Certificate of Professional Development

IV. MERCK/MRL EMPLOYMENT HISTORY

Vice President, Vaccines/Infectious Diseases (VID) Therapeutic Areas Global Regulatory Affairs and Clinical Safety (GRACS)	March 2016 – present
Vice President, Vaccines/Infectious Diseases (VID) Therapeutic Areas, Worldwide Product Labeling and Office of Promotion & Advertising Review, Global Regulatory Affairs and Clinical Safety	August 2014 – March 2016
Vice President, Vaccines/Infectious Diseases (VID) and Worldwide Product Labeling, Global Regulatory Affairs	Sept 2013 – July 2014
Vice President, Global Regulatory Affairs, WRG-3 (Vaccines)	Dec 2012 – August 2013
Executive Director, WRG-3, Therapeutic Area Lead, Vaccines and Infectious Diseases (Previously), Global Strategic Regulatory Development, now GRSPS	April 2007 – November, 2012
Therapeutic Area Lead, WRG-3, Infectious Disease and Vaccines, Global Strategic Regulatory Development	May 2006 – April 2007
Senior Director, Worldwide Regulatory Affairs, Vaccines/Biologics	June 2003 – May 2006
Senior Director, Global Strategic Regulatory Development, Biologics and Vaccines	June 2002 – June 2003
Director, Regulatory Liaison, Domestic	May 2001 - June 2002

IV. NON-MERCK EMPLOYMENT HISTORY

Sandoz and Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation Medical Director, Internal Medicine, Dermatology and Infectious Disease	1999 - 2001
--	-------------

V. ADDITIONAL TRAINING

Research Training

Wistar Institute, Visiting Scientist 1995 – 1997
(areas of research included: gene therapy, carcinogenesis, cell culture, tissue engineering and wound care, and melanoma)

VI. PUBLICATIONS AND PATENTS

Publications

Nelson JC, Atillasoy ES, Mazure C, Jatlow PI. Hydroxydesipramine in the Elderly. *J Clin Psychopharmacol* 8(6): 428-33, 1988.

Atillasoy ES. Humanities in Medicine. *JAMA* 262: 9, 1260, 1989.

Atillasoy ES, Burtis WJ, Milstone LM. Immunohistochemical Localization of Parathyroid Hormone-related protein (PTHrP) in Normal Human Skin. *J Invest Dermatol* 96(2); 277-80, 1991.

Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate Induces Differentiation of Human Keratinocytes. *Proc Natl Acad Sci* 89(2): 594-8, 1992.

Gaich G, Orloff JJ, Atillasoy ES, Burtis WJ, Ganz MD, Stewart AF. Amino-terminal Parathyroid Hormone-Related Protein: Specific Binding and Cytosolic Calcium Responses in Rat Insulinoma Cells. *Endocrinology* 123(3): 1402-9, 1993

Atillasoy ES. Multicentric Reticulohistiocytosis: Case Report. CD-ROM, *Am Acad of Dermatol*. 1994

Atillasoy ES, Weinberg J, et al. Adenocarcinoma of the Breast Presenting as a Keloid. *J. Geriatric Dermatol*, 3(5): 183-185, 1995

Weinberg JM, Baxt RD, Egan CL, Rook AH, Atillasoy ES, Regsdale BD. Mucormycosis in a Patient with Acquired Immunoeficiency Syndrome. *Arch Dermatol*. 1997 Feb; 133(2):249-51. No abstract available.

Atillasoy ES, Santoro A, Puri N. Cutaneous Drug Reactions. *Asian Clinics of Dermatol* Vol 2, December 1996.

Egan C, Atillasoy ES, and Werth V. Case Report: Vulvar Melanoma. CD-ROM, *Am Acad of Dermatol*, 1996.

Manders S, Heymann WR, Atillasoy ES. Recurrent Toxin-mediated Perineal Erythema. *Arch of Dermatol* 132: 57-60, 1996.

Atillasoy ES, Elenitsas R, Soballe P, Herlyn M. UVB Induction of Epithelial Tumors in Human Skin Using a RAG-1 Mouse Xenograft Model. *J Invest Dermatol* December, 1997.

Weinberg JM, Baxt RD, Eagan CL, Rook AH, Atillasoy ES, Ragsdale BD. Mucormycosis in a Patient with Acquired Immunodeficiency Syndrome. *Arch Dermatol*. Feb 1997. 133 (2).

Atillasoy, ES, Overview of Atopic Dermatitis. Editor Monograph and Slide Set, Novartis Pharmaceuticals, June 1998 – 2000

Sauter E, Klein-Szanto AJP, Atillasoy ES, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-Induced Squamous Epithelial and Melanocytic Cell Changes in a

Xenograft Model of Cancer Development in Human Skin. *Molecular Carcinogenesis* 23: 168-174, 1998.

Atillasoy ES, Soballe P, Elenitsas R, Nesbit M, Seykora J, Herlyn M. UVB Induces Atypical Melanocytic Lesions and Melanoma in Human Skin. *Am J Pathology* 152: 1179-1186, 1998

Atillasoy ES, et al. The Role of Anti-Fungal Agents in Immune-Compromised Patients. *Postgraduate Medicine* (in preparation) 2001.

Hazen KC, Moon AE, and Atillasoy ES. Susceptibility Testing of Anti-Dermatophyte Agents Using a Human Skin Construct. *J Clin Microbiol* 2001.

Rich P, Karchmer AW, Atillasoy ES. The Efficacy and Safety of Terbinafine in Diabetic Patients: A Multicenter Trial in Toenail Onychomycosis. *Clin Therapeutics* 2001.

Smith EB, Stein LF, Fivenson DP, and Atillasoy ES. The Safety of Terbinafine in Patients Over the Age of 60 Years: A Multicenter Trial in Onychomycosis of the Feet. *Int J Dermatol.* 2000 Nov; 39(11):861-4.

Atillasoy ES (editor) Current and Investigative Uses of Graftskin in Wound Care. *Journal Suppl Wounds.* 2000; 12 (5 Suppl A): 1A-79A.

Atillasoy ES, Santoro A, Weinberg JM. Lymphoedema Associated with Kaposi's sarcoma. *J Eur Acad Dermatol Venereol.* July 2001. 15 (4)

Atillasoy ES (Editor). Use of Terbinafine in the in HIV Positive and Diabetes Patients with Dermatophytosis. *Cutis* (Supplement) July 2001. Vol. 68 1-40S.

Elewski B, Leyden J, Atillasoy ES. The Infection Confirmation Survey (Onychomycosis). *Archives of Internal Medicine* 2002.

Jansen DA., Asgari MM, Atillasoy ES, LM Mileston. Clinical and in Vitro Responses of Bilayered Skin Construct (Graftskin) to Meshing. *Arch Dermatol*; June 2002. 138 (6) pp 843-844

Atillasoy ES, (Contributor and author) "Skin Cancers and Non-Cancerous Skin Growths," Merck Manual, Home Edition, 2003 edition

Rich P, Harkless LB, Atillasoy ES. Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients with Diabetes. *Diabetes Care*, May 23, 2006 (5): 1480-1484.

Amitava Mitra and Ercem Atillasoy (2012). Topical Therapies for Psoriasis. In *Psoriasis*, Jennifer Soung and Bonnie Koo (Ed

VII. PRESENTATIONS

Society for Bone and Mineral Research, Atlanta, GA, 1990

Society for Investigative Dermatology, Washington, D.C., 1990

Philadelphia Dermatological Society, 1992-5

Pennsylvania Academy of Dermatology, Hershey, PA, 1993

Duhring Conference, University of Pennsylvania, 1992-5

American Academy of Dermatology (AAD), Washington, D.C., 1993

Atlantic Dermatologic Society, Philadelphia, PA, 1994

Hacettepe University Medical Center, Ankara, Turkey, 1995

American Academy of Dermatology, New Orleans, LA, 1995

American Academy of Dermatology, Washington, D.C., 1996

Society for Investigative Dermatology, Washington, D.C., 1996

American Academy of Dermatology, San Francisco, CA, 1996

Society for Investigative Dermatology, Cologne, Germany, 1998

Skin Cancer Awareness Conference, New York, 1998

Department of Dermatology, Yale University, New Haven, CT, 1998

Department of Surgery, Walter Reed Hospital, Washington, D.C., 1998

American Academy of Dermatology, Orlando, FL, 1998

American Academy of Dermatology, New Orleans, LA, 1999

University of Medicine and Dentistry (UMDNJ), Newark, NJ, 1999

European Academy of Dermatology and Venereology, Amsterdam, Holland, 1999

American Academy of Dermatology, San Francisco, CA, 2000

Dept of Pharmacology, Invited Speaker, Tissue Engineering, Vanderbilt Medical School, Nashville, TN, 2000

InterScience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, 2000

PRESENTATIONS (cont'd)

American Academy of Dermatology, Infectious Diseases in Dermatology; Washington, D.C., 2001

Grand Rounds, Vaccines in Dermatology, Department of Dermatology, Yale University, 2003

Duhring Presentation, Vaccine Development; Grand Rounds, Department of Dermatology, University of Pennsylvania 2015

Panel Member, Regulatory Pathway for Licensure of Ebola Vaccines, Coalition for Epidemic Preparedness Innovations (CEPI) meeting, Washington, DC, March 2017

Invited Keynote Speaker—Japan DIA meeting, Vaccine Development and Policy Trends in the United States, Tokyo, Japan; November 2018.